Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer

The companion diagnostic test for checkpoint inhibitor immune therapy is an immunohistochemical test for PD-L1. The test has been shown to be reproducible for expression in tumor cells, but not in immune cells. Immune cells were used in the IMpassion130 trial which showed PD-L1 expression was associ...

Full description

Saved in:

Bibliographic Details
Published in:	Breast cancer research : BCR 2019-06, Vol.21 (1), p.72-3, Article 72
Main Authors:	Rimm, David L., Han, Gang, Taube, Janis M., Yi, Eunhee S., Bridge, Julia A., Flieder, Douglas B., Homer, Robert, Roden, Anja C., Hirsch, Fred R., Wistuba, Ignacio I., Pusztai, Lajos
Format:	Article
Language:	English
Subjects:	Analysis Atezolizumab B7-H1 Antigen - genetics B7-H1 Antigen - metabolism Biomarkers Biomarkers, Tumor - genetics Biomarkers, Tumor - metabolism Biomedical and Life Sciences Biomedicine Breast cancer Cancer Research Carcinoma, Non-Small-Cell Lung - diagnosis Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - metabolism Care and treatment FDA approval Female Funding Gene expression Humans Immune checkpoint Immunohistochemistry Immunotherapy Lung cancer Medical research Medical tests Monoclonal antibodies Non-small cell lung cancer Oncology PD-L1 PD-L1 protein Physicians Prognosis Small cell lung cancer Studies Surgical Oncology Targeted cancer therapy Triple Negative Breast Neoplasms - diagnosis Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - genetics Triple Negative Breast Neoplasms - metabolism Triple-negative breast cancer Tumor cells Tumors Viewpoint
Citations:	Items that this one cites Items that cite this one
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!